In this article, we will look at Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now.
Trump Incentivizes Pharmaceuticals to Build Domestic Manufacturing Capacity
Domestic manufacturing in the pharmaceutical industry has fallen considerably in the last decades, with most active ingredient production moving to China and other countries. According to the Food and Drug Administration, this trend largely emerged due to the low labor costs and other factors in the process.
According to statistics by consulting firm EY, the United States imported around $203 billion in pharmaceutical products in 2023 alone. Around 73% of these imports came from Europe, primarily Germany, Ireland, and Switzerland. However, this trend is likely to change in the future.
On May 5, CNBC reported that President Trump signed an executive order incentivizing prescription drug manufacturing in the United States. With potential tariffs on imported medicines looming, the order streamlines the process for pharmaceutical companies to build new production sites in the country.
Trump’s order directed the Food and Drug Administration to streamline reviews and remove unnecessary requirements to slash the time it usually takes to approve manufacturing plants in the United States. According to a White House fact sheet, the order entails working with domestic drugmakers to “provide early support before facilities come online.” CNBC reported that the order also directed the FDA to increase the inspection fees for foreign manufacturing plants and enhance the “enforcement of active-ingredient source reporting by overseas producers.”
The FDA’s commissioner, Marty Makary, said the order would allow the agency to conduct more new manufacturing site inspections with the same resources. The agency would also increase foreign drug facility inspections, going from announced to “surprise” visits. Makary said:
“We had this crazy system in the United States where American pharma manufacturers .. are put through the ringer with inspections, and the foreign sites get a lot easier with scheduled visits, while we have surprise visits.”
According to White House estimates, building new pharmaceutical manufacturing capacity can take 5 to 10 years, which the administration considers “unacceptable from a national-security standpoint.” President Trump said the following about the situation in a fact sheet:
“We don’t want to be buying our pharmaceuticals from other countries because if we’re in a war, we’re in a problem, we want to be able to make our own. As we invest in the future, we will permanently bring our medical supply chains back home. We will produce our medical supplies, pharmaceuticals, and treatments right here in the United States.”
READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 11 Most Promising Future Stocks According to Hedge Funds.
Domestic Manufacturing Investments Flare Up
In addition to the FDA, Trump’s order directed the Environmental Protection Agency to “accelerate the construction of facilities” related to drug manufacturing and their ingredients. This order came ahead of President Trump’s potential tariffs on pharmaceuticals imported into the United States, who said on May 5 that he would announce the pharmaceutical-specific tariffs in the coming two weeks. These circumstances have already led to a fresh wave of domestic manufacturing investments from several top drugmakers. However, some pharmaceutical companies are also pushing back on these plans, claiming that the tariffs’ threats are hindering further US investments in R&D and manufacturing.
CNBC reported that, according to an April release for GlobalData, reshoring manufacturing in the industry can result in a more robust drug supply chain, slashing the risk of disruption. However, it could raise drug prices and production costs substantially, leading to affordability concerns.
With these trends in view, lets look at the 12 best pharma stocks to buy now amid a domestic manufacturing boom.
A well-stocked pharmacy shelf full of the company’s pharmaceuticals, nutraceuticals, over-the-counter medications, and health care products.
Our Methodology
We sifted through stock screeners, financial media reports, and ETFs to compile a list of 25 best pharma stocks and then chose the top 12 with the highest number of hedge fund holders as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey’s database. The list is ordered in ascending order of hedge fund sentiment.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (see more details here).
Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now
12. GSK plc (NYSE:GSK)
Number of Hedge Fund Holders: 38
Formerly known as GlaxoSmithKline, GSK plc (NYSE:GSK) is a global biopharma company that develops and distributes a range of vaccines, medications, and consumer health items. It is based in the United Kingdom and has over 20 vaccines in its portfolio. The company also develops cancer treatments for multiple myeloma, ovarian cancer, and endometrial cancer, among others. It takes the 12th spot on our list of the best pharma stocks to invest in amid the ongoing domestic manufacturing boom in the sector.
The company is advancing its share buyback program and announced the purchase of 680,805 of its ordinary shares on May 8, which will be held as treasury shares. The initiative aims to enhance the company’s shareholder value and optimize its capital structure.
GSK plc (NYSE:GSK) also recently announced positive results from its GLISTEN phase III trial of linerixibat, which deals with primary biliary cholangitis (PBC). The results reported considerable improvements in itch-related sleep interference and itch severity, highlighting the treatment’s potential to address an important symptom of PBC.
On April 30, GSK plc (NYSE:GSK) reported strong financial performance in its fiscal Q1 2025 results, with its oncology sales surging by 53%. This growth was supported by notable performances from Jemperli and AGILE, which more than doubled their sales. The company generated more than £1 billion in cash from operations, which reflects its solid operations.
Analysts are also bullish on the stock because of the notable performance of its specialty medicine segment, which is GSK plc’s (NYSE:GSK) largest business area. It underwent a significant 17% growth in the quarter, supported by key contributions from oncology, respiratory immunology, and HIV treatments, reflecting its focus on high-growth therapeutic areas.